Latest Advances in Oncology: Scientific Review

Cancer's manipulation of the immune system

Researchers from MSK and Weill Cornell Medicine have discovered that cancer can manipulate the STING immune pathway. This alteration suppresses anti-tumor immunity, aiding cancer metastasis. This finding could reshape the approach to STING agonist drugs in clinical trials.

Read the article

Advancements in liquid biopsy technologies

Liquid biopsy technologies are revolutionizing precision oncology. These technologies analyze biological fluids for early cancer detection and personalized treatment. The 7th Annual Liquid Biopsy for Precision Oncology Summit highlighted the progress and challenges in this area.

Read the article

Understanding glioblastoma's resistance to immunotherapy

While some tumors that metastasize to the brain respond to immunotherapy, glioblastoma remains resistant. Research from Emory University suggests that lymph nodes play a pivotal role in this differential response. The study emphasizes the potential of enhancing T cell activation as a prospective treatment strategy.

Read the article

Chemotherapy's Unintended Awakening of Breast Cancer Cells

Chemotherapy might inadvertently awaken dormant breast cancer cells, leading to renewed growth. The awakening is driven by the release of two cell-signaling cytokines following the impact of chemotherapy on stromal cells. This discovery suggests a new treatment approach combining a MEK inhibitor with docetaxel.

Read the article

Scientific Application Note

COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy.

Jun 29th

COVID-19 and CANCER With the spread of coronavirus disease 2019 (COVID-19), countries and states have instituted lockdowns. These decisions have been difficult and are sometimes described as benefiting the public health at the expense of...

Press Release

Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia

Jul 13th

NTRK biomarker testing to identify patients most likely to benefit from treatment with targeted TRK inhibitors therapies. OncoDNA, Tamkin Al-Seha Medical and Bayer Saudi Arabia announced today a new partnership to broaden access to Neurotrophic...

Scientific Application Note

IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric.

Jun 22nd

FDA approves pembrolizumab for adults and children with TMB-H solid tumors On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult...

Scientific Review: Latest Discoveries in Oncology

Cancer's manipulation of the immune system

Advancements in liquid biopsy technologies

Understanding glioblastoma's resistance to immunotherapy

Chemotherapy's Unintended Awakening of Breast Cancer Cells

You may also be interested in these resources

COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy.

Collaboration between Bayer Saudi Arabia LLC, OncoDNA and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia

IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric.